Kite Pharma

Kite Pharma, established in 2009, is a prominent biopharmaceutical company dedicated to advancing cancer immunotherapy through innovative cell therapy. The organization specializes in engineered T cell therapy, focusing on the treatment of hematologic malignancies. By reengineering a patient's own immune cells to target cancer cells individually, Kite Pharma provides a transformative approach to oncology that differs significantly from traditional pharmaceutical manufacturing. The company remains committed to enhancing accessibility for eligible patients while driving research in the field of personalized medicine.

Operating with a workforce of 1,000-5,000 employees, Kite Pharma maintains a robust operational footprint across 7 global locations. The company manages dedicated cell therapy manufacturing facilities in California, Maryland, and the Netherlands, ensuring high-quality production standards for its specialized treatments. Meet Kite Pharma's team to learn about the leadership and scientific expertise driving these complex manufacturing processes. Their infrastructure supports the commercialization of advanced therapies, positioning the firm as a key player in the global healthcare sector.

Kite Pharma competes within a dynamic market alongside entities such as Legend Biotech, Ultragenyx, and Sarepta Therapeutics. With annual revenue reaching $675.1M, the company continues to scale its operations and expand its therapeutic pipeline. Explore financial highlights to review detailed metrics regarding their growth and market performance. As a leader in the biopharmaceutical industry, Kite Pharma leverages its specialized research and development capabilities to address critical unmet needs in cancer treatment, maintaining a strong competitive position through continuous innovation and strategic investment in cell-based technologies.